Table 2.

Patient characteristics for RPFNA

Women enrolled in study106
Bilateral RPFNA56
Unilateral RPFNA50
RPFNA samples collected162
RPFNA samples with insufficient epithelial cell count42
Subjects lacking a minimum of one RPFNA sample with sufficient epithelial cell count20
RPFNA samples (from subjects) submitted for analysis120 (86)

n = 86
Average age and range (y)47 (29-66)
Race
    Caucasian74 (86%)
    African-American12 (14%)
Menopausal status
    Postmenopausal26 (30%)
    Premenopausal/perimenopausal60 (70%)
Hormone replacement use
    Current2 (2%)
    Ever-use12 (14%)
    Never-use72 (84%)
Antiestrogen therapy (at the time of RPFNA)
    Tamoxifen2 (2%)
    Raloxifene2 (2%)
    Aromatase inhibitor2 (2%)
Family history of breast cancer52 (60%)
Prior abnormal biopsies
    ADH13 (15%)
    LCIS4 (5%)
    DCIS11 (13%)
    Hx. contralateral breast cancer16 (19%)
Known BRCA1 mutation carriers2
Known BRCA2 mutation carriers2
  • Abbreviations: LCIS, lobular carcinoma in situ; DCIS, ductal carcinoma in situ.